Source comparison
Head-to-Head Comparison Table
Peptide length 15 amino acids (1,419 Da) 43 amino acids (4,964 Da) Origin Gastric protein partial sequence (synthetic) Thymosin Beta-4 natural protein (synthetic) Primary mechanism VEGFR2 upregulation → angiogenesis G-actin sequestration → directed migration S
This comparison does not assign a generated winner or score.
- Peptide length
- 15 amino acids (1,419 Da)
- 43 amino acids (4,964 Da)
- Origin
- Gastric protein partial sequence (synthetic)
- Thymosin Beta-4 natural protein (synthetic)
- Primary mechanism
- VEGFR2 upregulation → angiogenesis
- G-actin sequestration → directed migration
- Secondary mechanism
- eNOS/NO pathway (L-NAME confirmed)
- Arp2/3-branched actin / lamellipodia formation
- Migration mechanism
- FAK-paxillin phosphorylation
- G-actin/Arp2/3 polymerisation
- Scratch assay closure (24h)
- +38–52% vs vehicle (FAK-dependent)
- +38–52% vs vehicle (actin-dependent)
- Pathway inhibitor
- L-NAME (NO), PF-573228 (FAK), anti-VEGFR2 Ab
- Cytochalasin D (actin), anti-TB-500 Ab
- CD31+ MVD (wound, day 7)
- 9.2/HPF vs vehicle 6.4 (+44%)
- 9.4/HPF vs vehicle 6.4 (+47%)
- GI healing evidence
- Strong (gastric ulcer, colitis, anastomosis)
- Minimal — not primary research area
- Neurological evidence
- Strong (TBI, spinal cord, BBB penetration)
- Limited — dopamine modulation reported
- Cardiac progenitor activation
- Not demonstrated
- Strong (epicardial progenitor reactivation)
- Anti-fibrotic evidence
- Limited — collagen quality improvement indirect
- Strong — reduces fibrosis in wound and cardiac models
- Oral activity in animal models
- Yes — gastric acid stable, orally active
- Limited — typical peptide oral degradation
- Published studies (dedicated)
- 100+ (primarily Šikirić group)
- Fewer (TB4 literature 50+ years broader)
- Human clinical trial data
- None (no completed Phase 3 trials)